Faculty of Medicine
Permanent URI for this communityhttps://repository.ukim.mk/handle/20.500.12188/14
Browse
15 results
Search Results
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, Evaluation of the surgical treatment of lung cancer(European Respiratory Society, 2024-09); ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Our experiences in the surgical approach to the treatment of lung cancer(Peytchinski Publishing Ltd, Pleven, Bulgaria, 2024); ; ; It is considered that 2,200,000 new patients with lung cancer are detected annually in the world (Globcan 2020), i.e. 1,135 in the Republic of North Macedonia (Globcan 2020), of which only 59 patients were surgically treated at the thoracic and vascular surgery clinic in 2022, which is 85% of the total surgically treated in the Republic of North Macedonia. The use of oncological drugs before surgical treatment can contribute to the application of surgery in cases where it was not possible, as well as reduce the tumor so that a less extensive surgical procedure can be applied. At the Thoracic and Vascular Surgery Clinic, of 59 patients surgically treated for lung cancer, 49 (83%) were treated with open anterolateral thoracotomy, and lobectomy with lymphadenectomy was most commonly performed in 41 (49.5%). Early diagnosis of lung cancer, using computed tomography screening, would allow the use of less aggressive approaches, such as videothoracoscopic surgery, robot-assisted surgery, and the use of less extensive lung resections such as segmentectomies with lymphadenectomy. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Modalities of surgical approach in the treatment of lung cancer(MIT University Skopje, 2024-03); ; ; ; Lung cancer is the most common malignancy in men and in the entire human population. It is considered that 2,200,000 new patients are detected annually in the world (Globcan 2020), i.e. 1,135 in the Republic of North Macedonia (Globcan 2020), of which only 59 patients were surgically treated at the thoracic and vascular surgery clinic in 2022, which is 85% of the total surgically treated in the Republic of North Macedonia.1 Numerous surgical techniques of lung resections are at our disposal in the treatment of lung malignancy, from wedge resection, segmentectomy, lobectomy and pneumectomy, which depends on the stage of the disease, localization of the tumor, involvement of other structures, functional reserves, etc. Lobectomy with lymphadenectomy is still a standard surgical technique in the treatment of early lung cancer (stage I and II non-small cell cancer). The use of oncological drugs before surgical treatment can contribute to the application of surgery in cases where it was not possible, as well as reduce the tumor so that a less extensive surgical procedure can be applied. At the Thoracic and Vascular Surgery Clinic, of 59 patients surgically treated for lung cancer, 49 (83%) were treated with open anterolateral thoracotomy, and lobectomy with lymphadenectomy was most commonly performed in 41 (49.5%).Early diagnosis of lung cancer, using computed tomography screening, would allow the use of less aggressive approaches, such as videothoracoscopic surgery, robot-assisted surgery, and the use of less extensive lung resections such as segmentectomies with lymphadenectomy. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Evaluation of the surgical treatment of lung cancer(Department of Anaesthesia and Reanimation, Faculty of Medicine, "Ss. Cyril and Methodius " University, Skopje, R.N. Macedonia, 2024-03); - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Genetic Alteration Profiling in North Macedonian Lung Cancer Patients(MDPI AG, 2025-10-10); ; ; ; Background/Objectives: Late diagnosis and inefficient treatment regimens lead to poor prognosis, with a low 5-year survival rate for both non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). New targeted therapeutic agents can be developed and introduced only by first discovering new driver oncogenes and with a thorough investigation of the known driver genes. The aim of the current study is to investigate the prevalence of alterations in the eight most frequently altered genes in lung cancer-BRAF, EGFR, KRAS, ALK, ROS1, HER2, PD-L1 and PIK3CA. Methods: Real-time polymerase chain reaction (RT-PCR) was used to detect KRAS and EGFR mutations, multiplex PCR and microarray hybridization for KRAS/BRAF/PIK3CA mutations. Immunohistochemical analysis was performed for the detection of ALK, HER2/NEU, ROS-1 and PD-L1 alterations. Results: Overall, 221/603 patients (36.65%) had at least one genetic alteration, of which 22 patients (3.65%) had two genetic alterations and two patients had more than two genetic alterations. Additionally, 50 patients were identified with one or more KRAS mutations (8.29%), 45 patients with EGFR mutations (7.46%), and 1.82% with PIK3CA mutations and 0.66% with BRAF mutations. Furthermore, 50% of the co-occurring alterations were either on KRAS and PIK3CA genes (3/6), on KRAS and BRAF genes (2/6, 33.33%) or on EGFR and PIK3CA genes (1/6, 16.67%), and 10.45% of the patients exhibited PD-L1 overexpression, 5.31% ALK rearrangements, and 2.36% HER2/NEU expression, with no ROS-1 rearrangements detected. Conclusions: Comprehensive testing for somatic alterations in EGFR, BRAF, KRAS, and PIK3CA is significant in guiding therapeutic decisions in lung cancer management. Such testing should be routinely conducted to establish a thorough genetic profile of lung cancers in a manner that is both time-efficient and cost-effective. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, BRAIN METASTASIS FROM LUNG CANCER(Македонско лекарско друштво = Macedonian medical association, 2025-04); ; Lung cancer is the leading cause of global cancer incidence and mortality, accounting for 2,4 million new cases and 1,8 million deaths in 2022. The most common symptoms of lung cancer include persistent cough, hemoptysis, weight loss, chest pain and dyspnea. One of the most common metastatic sites of lung cancer is the brain, with intracranial involvement in approximately 20% of patients at the time of diagnosis, and although rare the initial presentation of the disease can derive from this site. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, SMOKING HABIT AS A RISK FACTOR ASSOCIATED WITH OCCURRENCE OF LUNG CANCER(Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, 2024-07); - Some of the metrics are blocked by yourconsent settings
Item type:Publication, SOCIO-DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF LUNG CANCER PATIENTS IN NORTH MACEDONIA(Macedonian Association of Anatomists, 2024-04); ; Nehteparova, MelihaLung cancer disease is one of the most common causes of mortality in the world, coming right after cardiovascular diseases. It is a big and is a special problem in the highly developed countries, especially in the USA, but also in developing countries. The reason for the research is the fact that the number of newly diagnosed and death cases from lung cancer is constantly growing, especially in the last few years. The aim of the study is to determine the influence of socio-demographic factors in the occurrence of lung cancer(gender, age, national and ethnic origin, place of residence) and smoking as the main risk factor associated with this neoplasm. The research is a descriptive study in which 82 patients with pathohistological confirmed lung cancer participated. It was implemented at the Institute for Oncology and Radiotherapy at the clinical center in Skopje for a period of 3 months. A total of 82 patients were registered from Institute for Oncology and Radiotherapy in Skopje, North Macedonia who were diagnosed with primary lung cancer. Of all, 64.7% of them were males and 35.3% were females. Histologically, 51.2% had adenocarcinoma, 25.6 had squamous cell carcinoma, 20.7% had small cell carcinoma and 7.4% had no small cell carcinoma. It was observed that the proportion of females diagnosed with primary lung cancer is increasing. Patients get diagnosed at a later stage of the disease, which calls for screening and early detection of lung cancer. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Video-assisted thoracic surgery (VATS) right lower lobectomy after neoadjuvant treatment – case report(2022-01-10); - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Current concepts in CT Diagnosis and TNM-8 staging of Lung Cancer(2023-11)Regardless of the colossal efforts in lung cancer treatment, the majority of patients will present at an advanced stage when any curative treatment will no longer be an option. The overall 5-year survival for all tumor stages is disturbingly low at 15%, and lung cancer is the leading cause of cancer-related deaths for both genders worldwide. Early diagnosis as well as appropriate radiological staging is of utter importance for patients with early-stage lung cancer that can greatly benefit from timely treatment. The current 8th revision of tumor, node, metastasis (TNM) staging system accepted by The International Association for the Study of Lung Cancer (IASLC) and the American Joint Committee on Cancer (AJCC) was published in January, 2017, and the edition has committed some major alternations, including modification of the T classification based on 1 cm increment, down staging of the T descriptor disregarding its distance from carina (T2), integrating total and partial atelectasis/pneumonitis into the same T category (T2), upstaging diaphragmatic invasion to T4, new classification concepts of adenocarcinoma in situ and minimally invasive adenocarcinoma for pure and part-solid ground-glass nodules, and further division of extra thoracic metastasis into M1b and M1c based on their number and location. There is an agreement for some ambiguous conditions, such as the classification of Pancoast tumor based on its invasion depth, as well as categorization of various sites of pulmonary involvement. The IASLC Staging Project has provided evidence based recommendations for the TNM Classification for Thoracic Cancers in the last 20 years. The upgraded 9th edition of the TNM will be published on January 1, 2024 and will consider new data elements, including genetic biomarkers, protein alterations, and copy number alterations. In order for a radiologist to present an accurate clinical stage of lung cancer using consistent standards introduced in the 8th edition of the TNM Lung Cancer Staging System, it is important to acknowledge the prospective difficulties and limitations of imaging interpretation.